<DOC>
	<DOCNO>NCT01409733</DOCNO>
	<brief_summary>The Aim evaluate safety efficacy TACE doxorubicin-loaded DC bead melanoma patient liver metastasis . This pilot study aim recruit 20 patient , feasibility study . patient profile patient stage IV Melanoma liver metastasis .</brief_summary>
	<brief_title>TACE With Drug Eluting Beads Loaded With Doxorubicin Liver Metastases From Melanoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>1 . Patients unresectable , measurable disease define least one lesion accurately serially measure per modify RECIST EASL criterion ( 2D/3DEASL ) MRI ( Extent Necrosis ) 2 . Patients ≥ 18 year age , &gt; 35kg , race sex , histological radiological proof melanoma liver 3 . ECOG performance status &lt; 3 . 4 . Patient chooses participate sign informed consent document . 5 . Patients unilobar disease treat superselectively single session patient bilobar disease lobes able treat within 3 4 week separate session . 6 . Patients patent main portal vein . 7 . Ocular melanoma allow . 8 . Patients clinically radiologically stable brain metastasis melanoma include . 9 . Patients liver dominant disease ( &gt; 50 % overall tumor burden ) . 10 . Prior systemic therapy metastatic disease allow . 11 . Nonpregnant acceptable contraception premenopausal woman fertile men . 12 . Hematological function : ANC ≥1.5 x 109/L , platelet ≥ 75 x 109/L , INR &lt; 1.3 ( patient therapeutic anticoagulant eligible ) . 13 . Adequate renal function : Creatinine ≤2.0mg/dl GFR &gt; 30 . 14 . Adequate liver function : total bilirubin ≤ 2.5 mg/dl , ALT , AST ≤ 5 time ULN , albumin ≥ 2.5mg/dl . 15 . All toxic effect prior therapy must resolve ≤ Grade 1 unless otherwise specify 1 . Women pregnant breast feeding . 2 . Patients eligible curative treatment resection radiofrequency ablation . 3 . Active bacterial , viral fungal infection within 72 hour study entry . 4 . Previous concurrent cancer distinct primary site histology cancer evaluate study except cervical carcinoma situ , treat basal cell carcinoma , superficial bladder tumor ( TA , Tis &amp; Ti ) cancer curatively treat &lt; 5 year prior study entry . 5 . Contraindication hepatic artery embolization procedure : Severe peripheral vascular disease preclude catheterization . 6 . Large shunt determine investigator ( pretesting TcMAA require ) time first angiogram . 7 . Hepatofugal blood flow . 8 . Main portal vein occlusion ( e.g . thrombus tumor ) . 9 . Recovery major trauma include surgery within 4 week prior administration study treatment . 10 . Allergy contrast medium manage standard care ( e.g . steroid ) , make magnetic resonance imaging ( MRI ) compute tomography ( CT ) contraindicate . 11 . Advanced liver disease ( &gt; 80 % liver replacement ) . 12 . Other significant medical surgical condition , medication treatment would place patient undue risk would preclude safe use chemoembolization would interfere study participation . 13 . Ongoing systemic cancer treatment . 14 . Any contraindication Doxorubicin administration : 15 . WBC &lt; 3000 cells/mm3 16 . Neutrophils &lt; 1500 cells/mm3 17 . Deficient cardiac function define LVEF &lt; 50 % normal 18 . Allergy Doxorubicin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
</DOC>